Wall Street analyst estimates for Rallybio Corporation (RLYB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.44 |
Valuation Ratios
| P/E Ratio | 2.14 |
| Price / Book | 1.02 |
| EV / EBITDA | -0.11 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $636000 | $858000 |
| Cost of Revenue | $26344 | $62030 | $109000 | 0 | $150000 | $39.5M | $92000 |
| Gross Profit | -$26344 | -$62030 | -$109000 | 0 | -$150000 | -$38.9M | $766000 |
| Research & Development | $11.4M | $17.6M | $26.9M | $40.7M | $53.5M | $41.5M | $19.6M |
| Selling, General & Admin | $6.3M | $7.7M | $18.7M | $27.2M | $25.4M | $18.3M | $14.3M |
| Operating Expenses | $17.6M | $25.3M | $45.6M | $67.9M | $78.9M | $21.6M | $28.8M |
| Operating Income | -$17.6M | -$25.3M | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$28.1M |
| EBITDA | -$17.4M | -$25.2M | -$45.4M | -$67.7M | -$78.8M | -$60.4M | -$28.0M |
| Interest Expense | $39000 | $49000 | $10000 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$17.5M | -$26.5M | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M |
| Income Tax | 0 | -$15000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$17.6M | -$26.4M | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M |
| EPS | $-4.40 | $-9.52 | $-11.68 | $-16.72 | $-14.72 | $-10.64 | $-1.59 |
| EPS (Diluted) | $-6.32 | $-9.52 | $-11.68 | $-16.72 | $-14.72 | $-10.64 | $-1.59 |
| Shares Outstanding (Diluted) | $2.8M | $2.8M | $4.0M | $4.0M | $5.1M | $5.4M | $5.6M |
Price
| Price | $17.09 |
| Market Cap | $91M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BOLD · CVKD · IBIO · INTS · ITRM · KLTO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of RLYB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks